A Phase Ib/IIa trial of NM-002 for Short Bowel Syndrome (SBS)
Latest Information Update: 12 May 2020
At a glance
- Drugs Vurolenatide (Primary)
- Indications Short bowel syndrome
- Focus Adverse reactions
- Sponsors 9 Meters Biopharma [CEASED]
Most Recent Events
- 12 May 2020 New trial record
- 07 May 2020 According to a 9 Meters Biopharma media release, the company plans to initiate this clinical program along with Cedars-Sinai Medical Center.
- 04 May 2020 According to a 9 Meters Biopharma media release, the company has announced Closing of $22.5 Million private placement funding which will be used to support this trial.